Revolution Medicines, Inc. (RVMD)

Market Cap	14.75B
Revenue (ttm)	n/a
Net Income (ttm)	-960.98M
Shares Out	193.32M
EPS (ttm)	-5.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,051,288
Open	73.66
Previous Close	73.66
Day's Range	73.44 - 76.41
52-Week Range	29.17 - 76.41
Beta	0.99
Analysts	Strong Buy
Price Target	77.11 (+1.04%)
Earnings Date	Nov 5, 2025

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 13, 2020
• Employees: 534
• Stock Exchange: NASDAQ
• Ticker Symbol: RVMD
• Website: https://www.revmed.com

Analyst Summary

According to 18 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $77.11, which is an increase of 1.04% from the latest price.

Price Target

$77.11

(1.04% upside)

Analyst Consensus: Strong Buy